Gilead Made Gains In Oncology, Though Virology Remains King

New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021

 
• By Alaric DeArment
  
Digital illustration of Cancer cell in colour background
Gilead has made significant strides in developing its oncology business. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip